Good day, and welcome to the iAxis Alpha Virtual Best Ideas Summer Investment Conference 2026. Our next presenting company is Renovo Rx, Inc. If you'd like to ask a question during the webcast, you may do so at any point during the presentation by clicking on the Ask Question button on the left side of your screen. Type your question into the box and click Send. I'd now like to turn the floor over to today's host, Sean Begai, Chief Executive Officer of Renovo Rx, Inc. Please go ahead.

Thank you for the introduction, and thank you for the opportunity here, and thanks everyone for joining in. Sean Guy here, CEO of RenovoRx, and I'm also joined by my CFO, Chief Financial Officer, Mark Boll, who will chime in at the appropriate times. So I wanted to give you a little overview on our company, our background, how the technology works, and the opportunities that lay ahead of us. When we think about cancer and therapies in cancer, it's quite often a balance of trying to attack a tumor and not destroying the patient in the meantime. And what we've seen with therapeutic after therapeutic that the biggest blockbusters are, let's try to extend life by a few weeks to months, and hopefully we don't have the worst possible ever quality life for patients. And it's that kind of balance and give and take on both sides. At Renovo RX, we're trying to attack this very differently on is there a way that we can actually attack the tumor, keep the tumor at bay, extend life and also not destroy the patient in the process and maintain a relatively high quality of life and full function. And it looks like we're starting to achieve that. So, as a background, I'll go to our four looking statements, which can be found online as well. As a background, we're advancing an FDA-clear Renovocast device. So, as a life science company, we have both an FDA-clear device, which is now in the market, obtaining strong commercial momentum, We last announced we're in 16 active commercial centers purchasing devices and treating patients as of May 15th. And then beyond that, we're also pushing forward our TAMP, our trans arterial microperfusion platform in clinical trials and here commercially. On the commercial side with the device, we're pursuing a $400 million peak revenue opportunity with a much larger TAMP with additional applications as a standalone medical device. That's currently for sale right now and in, as I mentioned, 16 sites plus as of May 15th. And then on the clinical side, we're developing a combination therapy with our proprietary TAMP system, and we have been awarded three FDA orphan drug designations for this delivery mechanism in combination with those drugs. As far as a clinical development program, this is late stage on that aspect of the company where we're advancing a phase three study called TigerPak, and we anticipate enrollment completion in the coming days or weeks, marking a major milestone in a several-year program with final data expected late next year, mid to late next year. Specifically, the TigerPak trial is evaluating intra-arterial gemcitabine delivered via the RenovoCath FDA-cleared device, known as IHE, specifically in locally advanced pancreatic cancer. From a leadership team perspective, both on the board and the management team, we do have very experienced executives who have taken these types of products through clinical development and in the market. Let's talk about the platform first and the need here. So again, this is called the transarterial microprofusion platform, otherwise known as TAMP, utilized with a Renovocath FDA-cleared device. To step back and think about the physiology, when we think about tumors, we think of these balls of blood vessels with tumor cells, and generally speaking, there's a high blood flow to the tumors. So when you give systemic chemotherapy, you do have the opportunity where chemotherapy flows downstream with the blood flow into the tumor to affect the tumor cells. And these large blood vessels, which we call tumor feeders, actually end in the tumor. So it also provides for a local target where a physician can place a simple, small microcatheter, a plastic tube, inside the tumor directly to deliver some kind of therapy. On the flip side, there are many tumors in the body that aren't considered to be heavily vascularized or have large blood flow. These tumors, otherwise known as hypovascular, or not having many blood feeders, like pancreatic cancers, are relatively disconnected from the main circulatory system, and thereby, when systemic chemotherapy is given, very little gets to the tumor, but you have all the downsides of systemic toxicities. So our goal and approach is to drive high volumes of chemotherapy or therapy into tumors to get a higher local drug concentration and at the same time reduce the overall systemic exposure to the drug or the agent such that you don't have the systemic toxicity and side effects. So as a snapshot of what we've seen so far, in animal studies we have demonstrated a high local concentration. This is a log rank scale. We're seeing 100 times the concentration of drug, in this case gemcitabine, at the tissue site when delivered by our TAMP mechanism versus when you give it systemically. On the flip side, we do see a reduction in systemic exposure. So there's about a 50% reduction in systemic exposure of drug when given locally via our TAMP mechanism, which makes sense because we're localizing the therapy. This should and does lead to reduction of side effects down the road, and I'll share some data with you around that. The way our technology works is we've got the device called the RenovoCath device. It's a small device that's about two millimeters in diameter. A physician, namely interventional radiologist, placed this through a very tiny incision in a leg artery and then threaded into the circulatory system minimally invasively under X-ray guidance to position the device adjacent to a tumor. And again, so far these are tumors that largely don't have blood feeders that directly access the tumor. Once they position in the body, the physician is able to position two different balloons that are on the same system and adjust the distance between them such that they isolate blood flow so there's no leakage of therapy or chemotherapy. And over 20 minutes, they give an infusion of a very high volume and dose of therapy. In this case, with gemcitabine, for example, they give over a liter of fluid in a small space in a blood vessel that may be two to three milliliters in volume, and that creates a pressure head. So over 20 minutes infusion, within the first couple minutes, we start to see the pressure between the balloons increasing, eventually forcing the chemotherapy in this case or therapy outside the blood vessels to then saturate and bathe the local target and tumor and chemotherapy or therapy. And these aren't high pressures. As you can see by the chart here on the right, it's about 50 to 60 milliliters of mercury in an animal or maybe just over 100, 120 in a human to drive the therapy through existing microchannels to actually saturate and bathe the tumor in chemotherapy. Again, an animal is resulting in 100 times the concentration at the tissue site, which should have a great effect. So what does this mean for patients and physicians? Looking at other new therapies from a patient perspective, if you look at chemotherapy, generally patients go into infusion centers on a weekly basis or two out of four weeks so three out of four weeks. And in our case, they go every other week. So if the patient goes to the hospital once every two weeks, our treatments within the phase three trial have been up to eight treatments over four months, and it's an outpatient infusion. So they're in there for about 90 minutes on the table, approximately, with about a 20-minute infusion, and then discharged the same day as an outpatient procedure. And generally, these patients are not put under general anesthesia. So if you look at more complex, invasive devices and approaches to therapy, the patients have to be put under general anesthesia. In this case, they're just given medications to make them feel comfortable and then discharged the same day for the most part. From a physician perspective, it's relatively easy to understand and develop the techniques around this procedure because it's roughly the same skill sets as they use for liver-directed If you remember that previous slide I showed you, then the liver cancers, they do have these large tumor feeders where a physician can place a small microcatheter. So it's the same anatomy, same skill sets. So we're there for their first maybe two or three procedures with a proctor. And then after that, physicians are free to go on their own to continue treating that patient and other patients. And they can also train their colleagues as well. So it's a pretty low bar in terms of training physicians, which from a burn perspective actually does not require a major field force to support the technology. So far, experience has been primarily in locally advanced pancreatic cancer in the Phase III trial, and now that we've commercialized the technology, there are other areas where this can be expanded into. So the physicians that we've talked to so far have expressed interest in several areas where the tumors behave similar to pancreatic cancers without high blood flow or high supply of large tumor feeders to access. Namely, the interest level so far has been in locally advanced pancreatic cancer, LAPC. Beyond that, expanding into stage one and two, potentially four, pancreatic cancer, so looking to give before surgery for the rare patients who are identified early, or in patients who are even more advanced and have metastases, there are IITs or investigative initiative trials of interest right now to use the device commercially and further studies to be able to look into those markets as well. Beyond pancreatic cancer, CCA or cholangiocarcinoma is an area of interest where we should see some usage, hopefully in the not-too-distant future. Non-small-cell lung cancer, some of these tumors could be amenable to this type of approach given the vascularity or lack thereof in these tumors. Glioblastoma are brain tumors down the road, sarcomas or bone cancers potentially, and uterine tumors and fibroids as well. So there are a lot of growth areas of the technology beyond just pancreatic cancer. Let's shift gears and talk about the commercial approach first, and then we can talk about some of the data. As mentioned, we did commercialize the RenovoCat device based on inbound physician interest. This namely came out of physicians who are aware of our clinical trial and said, look, your device is cleared by the FDA. We're very interested in using this for patients who aren't tolerating systemic chemotherapy, which is the vast majority of them. Can we please buy your device and start treating patients? And finally, after a few years of discussing this as we're wrapping up the trial, now with good reimbursement in place for the physicians in the hospital, we've decided to go ahead and market the technology, have now launched the technology commercially. So talking about our commercial scale and the opportunities here, before I dive deeper in the market, I'd like to hand it over to Mark Fall, our CFO, to discuss the margin potential of the device and what our TAM looks like. Go ahead, Mark.

So when we look at our market and our business, we believe it's a high-margin, large market opportunity for our standalone device. If we look at the revenue potential for the company, we believe that approximately $400 million, that's based on delivery of $6,000 to $8,000 per unit and five to six treatments per patient. If we look at the business model itself, we believe it's really a high-margin business model. although we're ramping now our business and incurring losses we believe that by the second half of next year we'll be at a break-even point beyond that we believe it can really be a business that generates high operating margins so we believe gross margins will be 85 to 90% really requires low overhead and that's something that that Sean can touch upon shortly and it's a result we believe So this is a business that can generate 30% plus and operate in margins. We also have a highly defensible position of well-placed patents. As such, we think it creates really a defensible position for the company.

Thank you, Mark. And to expand on Mark's point about how this is low cost and low burn for us, when you look at our commercial efforts, it's a very targeted commercial effort that does not require a big field for us. And as we well know, new medical technologies often require large amounts of capital to fund a very large field force to do this market development work and drive revenue. In this case, it's very focused. If you look at, for example, the pancreatic cancer market, there are about 200 centers in the U.S. that treat or see the bulk of non-metastatic pancreatic cancers. Given that we've primarily had experience in the locally advanced or non-metastatic space, These are generally centers where patients go, once they learn that the tumor has not spread, they go to the large centers that have a large volume of surgeries to see if there's any way they can take the tumor out. Generally speaking, the patients are too advanced where the tumor has grown beyond the point of resection or removal, and they send the patients back to the oncologist to get standard of care systemic therapy. This TAMP mechanism provides another alternative where patients may not have the same side effects and actually may live longer as well. If you look at these 200 centers, it follows a standard 80-20 rule where actually 100 centers treat over 70% of the potential patients. And so with a targeted effort on the top 50 to 100 centers in the country, we could drive deep revenue. And it only takes a handful of sales reps to do this. We now have the commercial team in place with about five commercial reps in the field to drive deep penetration into this market. As far as our revenue to date, we can go to more detail later, but we did over a million dollars in revenue in 2025 to really explore the market development angle and understand the market before we scale in the wrong direction or with too much. And what we landed on is this perfect model of three to seven sales reps to be able to drive meaningful revenue for the company to drive towards a break-even endpoint, hopefully late next year. As far as where we are today, we did show $560,000 of revenue in Q1, and that was over 50% of our fiscal year 2025 total revenue, and we have guided that we expect our Q2 revenues this year to be even higher. A very important key performance index measurement that we want to look at is how fast we can get hospitals online. Once a hospital comes online, because each patient is such high revenue with multiple treatments, it only takes a handful of patients in each hospital to drive meaningful revenue, but not that many centers needed. If you look at 2025, we had about five active centers for the bulk of the year, adding a few more in December. What we've seen now is as of exiting the year with eight active centers, we last announced in mid-May we had 16 active cancer centers using the technology commercially and paying for the device with 32 additional centers in the pipeline. When I say in the pipeline, these are in the various stages of evaluation of the product to bring it on the shelf, having some of those approved already, and onboarding and looking for their first patient, giving us a total of 48 total centers that are either using the product right now or actively pursuing use of the product this year, which almost quadruples what we had just over a year ago. Now, we do expect some near-term variability with a handful of customers that seems to be smoothing out with this nice upward shift in revenue as we have more of these centers coming on board. So, in addition to looking at our revenue growth over the year, it's important to keep track of how many active centers we have going, as this really is a great predictor for future revenue one, two, three, four quarters down the road. The other major inflection point we anticipate this year is we are, as I mentioned, wrapping up our phase three trial with 15 active centers using the same technology specifically for pancreatic cancer. And of those, we've already started to transition them to be commercial users, treating the patients with the device commercially and paying for the product. And once we complete enrollment in the next few weeks here, or a couple weeks, we anticipate that these centers, many of these will transition by the end of the year, adding to those additional 48 centers we're looking at to really drive meaningful revenue later this year and into 2027. As far as the pipeline goes, I mentioned a few areas of interest from physicians. Specifically, we have announced publicly that there are two investigator-initiative trials that we have greenlit and are in the final processes of launching this year. One is specifically in gemcitabine, where we are looking at borderline pancreatic cancer and also metastatic pancreatic cancer. So, this expands beyond what we've been studying in the Phase III TigerPAC trial in just LAPC or locally advanced pancreatic cancer. We do have orphan drug designation in these indications. And then beyond that, we are launching what's called a metastatic cancer study using a different drug locally to show that this is a platform play. We can use almost any agent or multiple drugs through the device. So as new drugs come on the market, we can actually expand partnerships or uses both commercially and on the clinical research partnership side. So outside the commercial opportunity here, I'd like to switch gears and talk about the other asset in the company, as this is a dual-pronged approach with both a commercial asset that's launched recently that should drive us towards break-even cash flow, and also a phase three asset, late stage, that we're wrapping up the clinical trial right now for our TigerPak trial. To put this in context, let's look at what the current standard of care is in pancreatic As I mentioned earlier, we're looking for weeks to months of survival benefit, and so far we've only seen several weeks of benefit in large randomized studies. The most recent advancement we saw in 2013 of an approved product was the addition of Abraxin to gemcitabine, showing just a seven-week survival benefit, so a very narrow window of separation in survival curves, with a higher level of toxicity. So you don't have the benefit of both. You have that tradeoff. Patients live a few weeks longer, but they're sick for months during the entire treatment paradigm. In polling physicians, they said, look, if you can give me four months, three to four months of a survival improvement with an increased quality of life. This is something that's a game changer that will cause me to send almost all of my patients to the therapy. I'm not going to go the trial design too much in depth, but just very high level. The phase three trial is for treatment naive patients where they have upfront chemotherapy plus radiation and then randomized head-to-head again systemic chemotherapy, standard of care gemcitabine plus sabraxane for four months versus our TAMP therapy using gemcitabine with the RenovoCAP for four months and then continue for survival. Where we sit today in the trial, we've surpassed our first and second interim analyses with the data monitoring committee saying, go ahead, proceed, given how strong the data may be looking so far. And now we're on to our final analysis late next year as we anticipate completion of enrollment in days to weeks from now. Just to touch on the numbers here, we anticipate randomizing a total of 114 patients, and we need 86 events or deaths to do the final analysis, which we expect mid to late next year. From a data perspective, we did have the opportunity, given the early look, we had the first interim analysis was presented as a late breaker at ESMO GI in 2023, and that was a 30% look at Given that we skipped straight from a phase one to a phase three trial, we did demonstrate a six-month survival increase with our treatment of TAMP, given the renovo-calf with gemcitabine, versus standard of care gemcitabine plus abraxane. So where we expect patients to live 15 or 16 months, our patients were pushing two years of survival, trending towards a significant survival benefit. And the great part about this, as I mentioned, if you look at the flip side of it, there's not a payoff on the quality of life side. We actually saw, in addition to the potential survival benefit, we saw a significant reduction in side effects and toxicities, nearly 65% across the board, which is not surprising given that we're driving local concentration and reducing systemic therapy. And this data right here is really what's been driving the interest in our technology from physicians. In advance of final randomized data, there's interest of using our platform across the board because we're seeing such a better level of toxicity profiles in a space where beating up patients with chemotherapy is considered the standard of care. Beyond the Phase III TIGERPAC trial, as I mentioned, we are driving efforts on outside of Phase III trials, looking at investigative-initiative trials or registry studies using the commercially available product where we can drive both data and presentations and looking at spending indications. And it's important to note that these physicians and hospitals are paying for the technology and we can recognize this revenue in the process of doing these studies. So to round out the clinical trial, I'd like to wrap this up with kind of high level where we are in terms of finances. I'll turn it back over to Mark.

So had Sean touched on earlier, we had a very strong Q1 as far as revenues, $563,000 in revenue, 136% increase over Q4. We had guided to our sequential growth in Q2 over our Q1 results. We're well capitalized. We ended the Q1 with $12.4 million in cash. We have a very strong outlook for the rest of the year. We're targeting 36 active commercial sites at the end of the year during our call. We announced we had 16 active sites that signed up, another 32 that are in the pipeline. As a result of that, we'll feel confident in our revenue range for the year of $3 to $4 million in revenue for the year.

Thank you, Mark. These slides, of course, are on our website, so I'll skip through quickly. But as I mentioned, we have a strong management team, both on the management side and on the board, with the depth of experience, both in medical devices and on the biotech side, and also taking new therapies through clinical trial development and into deep commercialization. On the board side as well, one of our most recent board members added was Dr. Bob Spiegel, who was the Chief Medical Officer of Sherry and Plow, and is helping further drive advancement of our technology into other areas using more cost-effective clinical trials beyond the Phase III. And we have assembled an all-star team of luminaries in the field on different specialties that treat these types of tumors. Everything from surgical oncologists to medical oncologists, including Dr. Margaret Timpero, who's the chief of the NCCN Guideline Committee, who writes the guidelines on pancreatic cancer and radiation oncology as well. And then we've recently also assembled a team more to look at the commercial potential of the RenovoCat device in the interventional radiology space at luminaries in the field as well on that side. Lastly, just upcoming milestones. As you've seen, we're not a quiet company. We do have a lot of news flow that shows the shareholder value that we're building. As we're wrapping up the Phase III trial enrollment, we do have initial data coming, some coming out of the induction and radiation parts of the Phase III trial. We did recently present the PK data showing reduction in systemic toxicities. This will be in full publication later this year. Beyond that, we will give progress updates on the investigator initiative trials where the Renovo cap is being used commercially to show data in other areas beyond pancreatic cancer, and then, of course, how we're doing in terms of safety information across a broader range of solid tumors. One other notable is that we were named to the Fast Times, the Fast Company's annual list of the world's most innovative companies in 2026, which is a big achievement, which goes to really where this can make a major impact on medicine. Lastly, I'd like to leave you with a little bit on what we're doing for patients. So this has always been key to our mission with everyone employed at Renovo Rx, where we're seeing patients really potentially benefiting from this therapy. In the investor section of our website, if you go to news and clinical news, there are several stories that have been on various news channels of patients who have been treated with the TAMP therapy or the Renovo CAP, demonstrating the quality of life, potential improvements, and the hope for continued survival. And I come back to the point of this is a technology that's actually maybe benefiting patients across both spectrums. We can extend life potentially and also make it a life worth living by reducing those toxicities that you normally see with chemotherapy. At the same time, we're driving a highly profitable commercial business on our way there in the not-too-distant future. Thank you so much for your time, and at this point, we'll open for questions.

Speakers may access the questions by the Q&A tab. If you'd like to ask a question and you're a participant, and please click on the Ask Question button on the left side of your screen. Type your question into the box and click Send.

Okay, so the first question comes, what are the primary drivers behind your confidence in achieving the company's 2026 revenue guidance of $3 million to $4 million? Mark, would you like to take that one?

Sure. The number of active campus centers is really going to drive revenue. We targeted 36 for the year. As we mentioned on our call, Our Q1 conference call, we're at 16. We have another 32 in the pipeline. We feel that most, if not all, of those will come out and convert to active centers by the end of the year. So we feel very confident in our guidance that $3 or $4 million is a realistic goal for the company.

Thank you. There's a bunch here, so I'll pick a few of them, and then we'll come to the rest with post-follow-up. So, Mark, one of the questions is, does the $12 million in the bank get you to break even? Do you want to take that one?

I'm sorry. I didn't see the question.

It's towards the bottom. Does the $12 million in the bank get you to break even? The fact that we're well capitalized is something that's very important. So go ahead, Mark.

Yeah, I think that we'll get strongly into the second half of next year. I think at that point in time, we'll probably be looking at some additional, some small financing at that point in time. But for the most part, I think we're well-capitalized to get into that part of the year and beyond.

Thanks. There's a question of, with more than 750 procedures performed a day, what key lessons have you learned from real-world commercial use? This is a very important question because one of the reasons we didn't hire Salesforce off the bat is I wanted to make sure there weren't barriers to adoption and the market is as big as we believe it is. And we found that the technology is relatively easy for physicians to adopt and learn, and most patients that we've come across are amenable to the procedure. So we have seen that the technology does not need major modification, and there aren't major barriers to deep clinical adoption. There's another question with many investors still view RenovoRx as a clinical stage company. How should investors think about the standalone commercial opportunity for RenovoCat today? I think there are several positive answers from here, but maybe, Mark, I'll let you talk about the high growth and margin business first.

So, yeah, we continue to see strong growth for the companies. We see, you know, 85% operating, or excuse me, gross margins. Again, we have a low overhead, so we have most of the components in place to drive revenue for the next several years. So, you know, I think that we're well positioned to drive future revenue and eventually get to break even and beyond that. Again, we believe it's a high-margin business that can generate significant margins as we drive further revenue growth.

Thanks, Mark. And this kind of lays in an additional question is, beyond pancreatic cancer, which additional tumor types represent most attractive expansion for opportunities for a Novocath in the TAM platform? Another question talks about referencing a multibillion-dollar addressable market opportunity. So these fit together, and as we go beyond where we have experienced so far, which we believe is probably a total available market of $1 to $2 billion, achieving $400 million of peak sales with the RenovoCath. As there's interest beyond just locally advanced pancreatic cancer, which is 20,000 patients a year, there are another 40,000 pancreatic cancer patients that have metastases or can be removed surgically where there's interest in studying this. So the pancreatic cancer market beyond locally advanced is multibillion. Beyond that, cholangia carcinoma or a bile duct cancer would be a next target where there's interest in using the catheter commercially today and further clinical research trials. Non-small cell lung cancer down the road. So as a platform play, there's a lot of opportunity there. Coming back to the question Mark answered, is this a clinical story or a commercial story? And the amazing part is we actually have kind of both in the sense that you look at other companies like Chrysalis, Noble Cure, and DelCath are great analogs of the technology that we have on adjacent tumor spaces where their market caps are 250 million to three to 400 million to one to two billion. It shows where we could go, you know, sitting here at less than 100 million market cap with a commercial opportunity where we can break even in the not too distant future. And then on the kind of back end of that, we do have this clinical story where we're waiting for final data that could be even bigger. So it gives you two major opportunities to drive shareholder value at a relatively low valuation of where we sit today in a company that's very well capitalized and doesn't need to raise a lot of money any time in the near future. Another question is, you are targeting 36 active commercial centers by your end. What milestones should investors watch over the next several quarters to measure progress toward that goal? Mark, do you want to take that one?

Yeah, I just think continued revenue growth. As we, again, sign up more active campus centers, that should allow us to drive further revenue growth. And we feel very strongly we're well-positioned to see that kind of growth this year and then next year.

And the other measure I'd look at, so revenue growth is the obvious one. And as we talked earlier, one of the KPIs is looking at active centers. So going from 8 to 16, exiting 2025 to 16 by May, showing on a quarterly basis or even more, advancing quickly to that 36 goal and beyond, especially when we have over 48 total, including the active centers in the pipeline, it looks like we're well on our way to that target. So looking at revenue and active centers, just to reiterate what Mark said, is a great indicator of our current and future success. On that note, there's a question of active commercial centers, cancer centers doubled from 8 to 16 in recent months. What has been the biggest factor driving physician adoption of Novocath? This is actually an interesting question because the physicians coming to us saying we need another option is the biggest driver. Again, even with new technologies in the news like Revolution Medical, one of the biggest issues with cancer therapy to date is the toxicities and side effects. is that after two to six months of treatment, most patients can't tolerate the systemic therapy, and most therapies don't work drastically, so they often switch to local therapy like radiation, for example, which has not shown a survival benefit. And so this gives physicians an option where once they've exhausted a few months of chemotherapy with high toxicities, there's an opportunity to try something different that may reduce the side effects, make patients feel better overall, and give them hope that there's a survival possibility here to live weeks to months or maybe even years longer. We've had patients out three, four, five years since diagnosis. So the biggest driver is that really interest in trying to give another option. So with that, there are a few more questions there. Please feel free to reach out directly. But just to close up as we're a little bit over time here, just to kind of conclude what we're looking at, as we've seen for decades, cancer treatment has really been a blunt instrument. We flood the body with chemotherapy and hope we hit the target harder than it hits everything else, which is not the case. We're changing that model. Precision medicine is really rewriting the rulebook as we look at other therapy types. And companies that can deliver treatment directly to the tumor while sparing the rest of the body are solving for one of medicine's longest-standing problems. Our platform, powered by FDA-cleared RenovoCat device, is doing exactly that. And as I mentioned before, the fact that we were just named Fast Companies World's Most Innovative Companies of 2026 in the medical device category speaks for itself. I appreciate everyone's time and looking forward to continuing dialogue tomorrow.

Thank you. That concludes RenovarRx, Inc.'s presentation. You may now disconnect. Please conference the conference agenda for the next presenting company.